• Leukemias, lymphomas, and other hematologic cancers

Synribo Generic Name & Formulations

General Description

Omacetaxine mepesuccinate 3.5mg/vial; lyophilized pwd for SC inj after reconstitution; contains mannitol; preservative-free.

Pharmacological Class

Protein synthesis inhibitor.

How Supplied

Single-use vial—1


Generic Availability


Synribo Indications


Treatment of patients with chronic or accelerated phase chronic myeloid leukemia (CML) with resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKI).

Synribo Dosage and Administration


Induction: 1.25mg/m2 by SC inj twice daily (approx. 12hrs apart) for 14 consecutive days every 28 days, over a 28-day cycle. Repeat cycles every 28 days until hematologic response achieved. Maintenance: 1.25mg/m2 by SC inj twice daily for 7 consecutive days every 28 days, over a 28-day cycle, as long as clinically beneficial. Dose adjustments and modifications: see full labeling.


Not established.

Synribo Contraindications

Not Applicable

Synribo Boxed Warnings

Not Applicable

Synribo Warnings/Precautions


Risk of myelosuppression (thrombocytopenia, neutropenia, anemia) or hemorrhage (cerebral, GI). Monitor CBCs with platelets weekly during induction and initial maintenance cycles, then every 2wks during later cycles. Diabetes: monitor glucose levels frequently; if poorly controlled, avoid until glycemic control is established. Elderly. Embryo-fetal toxicity. Pregnancy (Cat. D); avoid. Nursing mothers: not recommended.

Synribo Pharmacokinetics

See Literature

Synribo Interactions


Avoid concomitant anticoagulants, aspirin, NSAIDs if platelets <50,000/microliters.

Synribo Adverse Reactions

Adverse Reactions

Thrombocytopenia, anemia, neutropenia, diarrhea, nausea, fatigue, asthenia, injection site reaction, pyrexia, infection, lymphopenia; bleeding, hyperglycemia.

Synribo Clinical Trials

See Literature

Synribo Note

Not Applicable

Synribo Patient Counseling

See Literature